Latest News

FDA Approves Monjuvi® (tafasitamab-cxix) in Combination With Lenalidomide for the Treatment of Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)




PLANEGG, Germany & MUNICH & WILMINGTON, Del.–(BUSINESS WIRE)—- $INCY–FDA Approves Monjuvi® (tafasitamab-cxix) in Combination With Lenalidomide for the Treatment of Adult Patients With Relapsed or Refractory DLBCL

Source link

Related posts

New cardiac pump clinically superior, safer for patients

Newsemia

Electric Stimulation Drastically Improves Memory of Older Folks

Newsemia

Dr Asim Hussain shifted to hospital 

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy

COVID-19

COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World